Literature DB >> 25851385

Direct extubation onto high-flow nasal cannulae post-cardiac surgery versus standard treatment in patients with a BMI ≥30: a randomised controlled trial.

Amanda Corley1, Taressa Bull, Amy J Spooner, Adrian G Barnett, John F Fraser.   

Abstract

PURPOSE: Patients with a body mass index (BMI) ≥30 kg/m(2) experience more severe atelectasis following cardiac surgery than those with normal BMI and its resolution is slower. This study aimed to compare extubation of patients post-cardiac surgery with a BMI ≥30 kg/m(2) onto high-flow nasal cannulae (HFNC) with standard care to determine whether HFNC could assist in minimising post-operative atelectasis and improve respiratory function.
METHODS: In this randomised controlled trial, patients received HFNC or standard oxygen therapy post-extubation. The primary outcome was atelectasis on chest X-ray. Secondary outcomes included oxygenation, respiratory rate (RR), subjective dyspnoea, and failure of allocated treatment.
RESULTS: One hundred and fifty-five patients were randomised, 74 to control, 81 to HFNC. No difference was seen between groups in atelectasis scores on Days 1 or 5 (median scores = 2, p = 0.70 and p = 0.15, respectively). In the 24-h post-extubation, there was no difference in mean PaO2/FiO2 ratio (HFNC 227.9, control 253.3, p = 0.08), or RR (HFNC 17.2, control 16.7, p = 0.17). However, low dyspnoea levels were observed in each group at 8 h post-extubation, median (IQR) scores were 0 (0-1) for control and 1 (0-3) for HFNC (p = 0.008). Five patients failed allocated treatment in the control group compared with three in the treatment group [Odds ratio 0.53, (95 % CI 0.11, 2.24), p = 0.40].
CONCLUSIONS: In this study, prophylactic extubation onto HFNC post-cardiac surgery in patients with a BMI ≥30 kg/m(2) did not lead to improvements in respiratory function. Larger studies assessing the role of HFNC in preventing worsening of respiratory function and intubation are required.

Entities:  

Mesh:

Year:  2015        PMID: 25851385     DOI: 10.1007/s00134-015-3765-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  35 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study.

Authors:  Benjamin Sztrymf; Jonathan Messika; Thomas Mayot; Hugo Lenglet; Didier Dreyfuss; Jean-Damien Ricard
Journal:  J Crit Care       Date:  2011-09-29       Impact factor: 3.425

Review 3.  High flow nasal oxygen in acute respiratory failure.

Authors:  J-D Ricard
Journal:  Minerva Anestesiol       Date:  2012-04-24       Impact factor: 3.051

4.  Comparing two methods of delivering high-flow gas therapy by nasal cannula following endotracheal extubation: a prospective, randomized, masked, crossover trial.

Authors:  D D Woodhead; D K Lambert; J M Clark; R D Christensen
Journal:  J Perinatol       Date:  2006-05-25       Impact factor: 2.521

Review 5.  Research in high flow therapy: mechanisms of action.

Authors:  Kevin Dysart; Thomas L Miller; Marla R Wolfson; Thomas H Shaffer
Journal:  Respir Med       Date:  2009-05-21       Impact factor: 3.415

6.  Effect of high-flow nasal cannula on thoraco-abdominal synchrony in adult critically ill patients.

Authors:  Taiga Itagaki; Nao Okuda; Yumiko Tsunano; Hisakazu Kohata; Emiko Nakataki; Mutsuo Onodera; Hideaki Imanaka; Masaji Nishimura
Journal:  Respir Care       Date:  2013-06-04       Impact factor: 2.258

7.  Use of a nasal continuous positive airway pressure mask in the treatment of postoperative atelectasis in aortocoronary bypass surgery.

Authors:  J C Pinilla; F H Oleniuk; L Tan; I Rebeyka; N Tanna; A Wilkinson; B Bharadwaj
Journal:  Crit Care Med       Date:  1990-08       Impact factor: 7.598

8.  Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients.

Authors:  A Corley; L R Caruana; A G Barnett; O Tronstad; J F Fraser
Journal:  Br J Anaesth       Date:  2011-09-09       Impact factor: 9.166

Review 9.  Extubation failure: magnitude of the problem, impact on outcomes, and prevention.

Authors:  Robert C Rothaar; Scott K Epstein
Journal:  Curr Opin Crit Care       Date:  2003-02       Impact factor: 3.687

10.  Effect of adding postoperative noninvasive ventilation to usual care to prevent pulmonary complications in patients undergoing coronary artery bypass grafting: a randomized controlled trial.

Authors:  Emad Al Jaaly; Francesca Fiorentino; Barnaby C Reeves; Philip W Ind; Gianni D Angelini; Scott Kemp; Robert J Shiner
Journal:  J Thorac Cardiovasc Surg       Date:  2013-04-11       Impact factor: 5.209

View more
  41 in total

1.  High flow oxygen cannula: the other side of the moon.

Authors:  Alexandre Demoule; Jordi Rello
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

2.  High-flow nasal cannula following extubation: is more oxygen flow useful after surgery?

Authors:  Emmanuel Futier; Samir Jaber
Journal:  Intensive Care Med       Date:  2015-06-13       Impact factor: 17.440

3.  High-flow nasal cannula oxygen therapy: more than a higher amount of oxygen delivery.

Authors:  Eric Maury; Mikael Alves; Naike Bigé
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

4.  High-flow nasal cannula in the postoperative period: is positive pressure the phantom of the OPERA trial?

Authors:  Lorenzo Ball; Lieuwe D Bos; Paolo Pelosi
Journal:  Intensive Care Med       Date:  2016-11-16       Impact factor: 17.440

5.  Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA).

Authors:  Emmanuel Futier; Catherine Paugam-Burtz; Thomas Godet; Linda Khoy-Ear; Sacha Rozencwajg; Jean-Marc Delay; Daniel Verzilli; Jeremie Dupuis; Gerald Chanques; Jean-Etienne Bazin; Jean-Michel Constantin; Bruno Pereira; Samir Jaber
Journal:  Intensive Care Med       Date:  2016-10-22       Impact factor: 17.440

6.  High flow nasal cannula in extubated patients: is it advantageous over conventional oxygen therapy?

Authors:  Jian-Jun Zhang; Bing Dai
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

7.  The role of high-flow nasal cannula therapy in patients with respiratory failure.

Authors:  Xuping Cheng; Weimin Zhang
Journal:  CMAJ       Date:  2019-01-14       Impact factor: 8.262

8.  High-Flow Oxygen and High-Flow Air for Dyspnea in Hospitalized Patients with Cancer: A Pilot Crossover Randomized Clinical Trial.

Authors:  David Hui; Farley Hernandez; Diana Urbauer; Saji Thomas; Zhanni Lu; Ahmed Elsayem; Eduardo Bruera
Journal:  Oncologist       Date:  2020-12-15

Review 9.  Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review.

Authors:  Laurent Papazian; Amanda Corley; Dean Hess; John F Fraser; Jean-Pierre Frat; Christophe Guitton; Samir Jaber; Salvatore M Maggiore; Stefano Nava; Jordi Rello; Jean-Damien Ricard; François Stephan; Rocco Trisolini; Elie Azoulay
Journal:  Intensive Care Med       Date:  2016-03-11       Impact factor: 17.440

10.  Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial.

Authors:  Elie Azoulay; Virginie Lemiale; Djamel Mokart; Saad Nseir; Laurent Argaud; Frédéric Pène; Loay Kontar; Fabrice Bruneel; Kada Klouche; François Barbier; Jean Reignier; Lilia Berrahil-Meksen; Guillaume Louis; Jean-Michel Constantin; Julien Mayaux; Florent Wallet; Achille Kouatchet; Vincent Peigne; Igor Théodose; Pierre Perez; Christophe Girault; Samir Jaber; Johanna Oziel; Martine Nyunga; Nicolas Terzi; Lila Bouadma; Christine Lebert; Alexandre Lautrette; Naike Bigé; Jean-Herlé Raphalen; Laurent Papazian; Michael Darmon; Sylvie Chevret; Alexandre Demoule
Journal:  JAMA       Date:  2018-11-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.